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Resistance to FasL and tumor necrosis factor-related
apoptosis-inducing ligand-mediated apoptosis in Sezary
syndrome T-cells associated with impaired death receptor and
FLICE-inhibitory protein expression
Abstract
Because of the low proliferative potential of tumor cells in patients with Sézary syndrome (SzS), their
accumulation has been suggested to be due to defective regulation of apoptosis. We analyzed the
sensitivity to soluble Fas-ligand (FasL) and tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL), 2 members of the TNF superfamily in peripheral blood leukocytes (PBL) from patients
with SzS. Compared with healthy donors, CD4(+) cells from patients with SzS were completely
resistant to FasL in 9 of 16 cases. Of these 9 FasL-resistant cases, 4 revealed a loss in Fas (CD95)
expression, whereas the remaining 5 exhibited normal or enhanced Fas expression. In the latter 5 cases,
the apoptosis inhibitor cFLIP was overexpressed in CD4(+)/CD26(-) tumor cells compared with
CD4(+)/CD26(-) cells from Fas-expressing FasL-sensitive patients and healthy donors. Furthermore,
resistance to TRAIL and tumor cell-restricted loss of TRAIL-receptor 2 were observed in 16 of 16 SzS
PBLs. It is noteworthy that resistance to FasL could be overcome by the use of a hexameric FasL or
upon exposure of SzS cells to interferon-alpha (IFN-alpha) or IFN-gamma, the latter by an increase of
Fas expression. Our data on primary SzS lymphocytes reveal frequent resistance to apoptosis induced by
FasL and TRAIL, which may contribute to their accumulation in patients with SzS and be relevant at a
therapeutic level.
doi:10.1182/blood-2007-08-109074 
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NEOPLASIA
Resistance to FasL and tumor necrosis factor-related apoptosis-inducing
ligand-mediated apoptosis in Se´zary syndrome T-cells associated with impaired
death receptor and FLICE-inhibitory protein expression
*Emmanuel Contassot,1 *Katrin Kerl,1 Ste´phanie Roques,2,3 Ryan Shane,4 Olivier Gaide,2,3 Marc Dupuis,5 Alain H. Rook,4
and Lars E. French1
1Department of Dermatology, Zu¨rich University Hospital, Zu¨rich, Switzerland; 2Louis-Jeantet Skin Cancer Laboratory, Department of Pathology and Immunology,
University Medical Center, Geneva, Switzerland; 3Department of Dermatology, University Hospital, Geneva, Switzerland; 4Department of Dermatology,
University of Pennsylvania School of Medicine, Philadelphia; and 5Topotarget Switzerland, Lausanne, Switzerland
Because of the low proliferative potential
of tumor cells in patients with Se´zary
syndrome (SzS), their accumulation has
been suggested to be due to defective
regulation of apoptosis. We analyzed the
sensitivity to soluble Fas-ligand (FasL)
and tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL),
2 members of the TNF superfamily in
peripheral blood leukocytes (PBL) from
patients with SzS. Compared with healthy
donors, CD4 cells from patients with
SzS were completely resistant to FasL in
9 of 16 cases. Of these 9 FasL-resistant
cases, 4 revealed a loss in Fas (CD95)
expression, whereas the remaining 5 ex-
hibited normal or enhanced Fas expres-
sion. In the latter 5 cases, the apoptosis
inhibitor cFLIP was overexpressed in
CD4/CD26 tumor cells compared with
CD4/CD26 cells from Fas-expressing
FasL-sensitive patients and healthy do-
nors. Furthermore, resistance to TRAIL
and tumor cell-restricted loss of TRAIL-
receptor 2 were observed in 16 of 16 SzS
PBLs. It is noteworthy that resistance to
FasL could be overcome by the use of a
hexameric FasL or upon exposure of SzS
cells to interferon- (IFN-) or IFN-, the
latter by an increase of Fas expression.
Our data on primary SzS lymphocytes
reveal frequent resistance to apoptosis
induced by FasL and TRAIL, which may
contribute to their accumulation in pa-
tients with SzS and be relevant at a thera-
peutic level. (Blood. 2008;111:4780-4787)
© 2008 by The American Society of Hematology
Introduction
Se´zary syndrome (SzS) is a leukemic variant of mycosis fungoides,
a cutaneous T-cell lymphoma showing distinct clinical, histologic,
immunologic, and genotypic features. SzS is characterized by the
clonal proliferation of skin-invasive CD4 T lymphocytes that
have the phenotype of mature helper T cells.1 Patients with SzS
manifest erythroderma, generalized lymphadenopathy, and promi-
nent immunologic defects as a result of the production of immuno-
suppressive T-helper 2 (Th2) cytokines and by the depressed
production of Th1 cytokines.1-3 The molecular cause of this Th2
shift remains to be identified, but its identification is likely to
provide new therapeutic possibilities, because biologic response
modifiers such as interferon- (IFN-), IFN-, and interleukin-12
(IL-12), which stimulate Th1 responses, have significant therapeu-
tic effects in SzS.4,5
Apoptosis can be triggered by a series of stimuli, among which
are signals generated by a family of transmembrane proteins—
called death receptors—that belong to the tumor necrosis factor
(TNF)-family of receptors. Six death receptors, namely Fas (CD95,
Apo-1), TRAIL-receptor 1 (DR4), 2 (DR5, Apo-2), TNF-receptor
1, TRAMP (DR3, WSL-1, Apo-3), and DR6 have been identified,6,7
and all contain a cytoplasmic sequence named “death domain” that
couples each receptor to caspase cascades essential for the induc-
tion of apoptosis.
The acquisition of resistance to apoptosis as one of the
mechanisms involved in tumorigenesis is well documented. In
many tumors, a decrease if not a loss of the expression of Fas
compared with nontumor counterparts has been reported. In
addition, mutations of Fas, TRAIL-R1, and TRAIL-R2 have been
reported in several human cancers.8-14 In addition to an impaired
expression of death receptors, aberrant expression of intracellular
apoptosis inhibitors has been reported in many cancers. Among
them, FLICE-inhibitory protein (cFLIP), which is highly homolo-
gous to caspases 8 and 10, contains a death effector domain through
which it can bind to FADD and is able to block the autoproteolytic
cleavage of caspase-8. An overexpression of cFLIP associated with
a high expression of Fas has been reported in FasL-resistant
Hodgkin/Reed-Sternberg cells, the malignant cells of classic
Hodgkin lymphoma.15 An overexpression of cFLIP in ovarian
cancer cells has been shown to be also associated with a resistance
to cisplatin-induced apoptosis in vitro.16 Similar observations were
also reported for non-Hodgkin lymphoma,17 bladder urothelial
carcinoma,18 pancreatic cancer, stomach cancer,19 and melanoma.20
Finally, mouse models of lymphoma well document evidence for a
role of cFLIP overexpression in tumor progression.21,22 Because of
the low replicative potential of Se´zary cells, their accumulation
may to some extent be due to a defect in apoptosis pathways.
Apoptosis defects in CTCL cell lines have recently been reported.
These defects have been shown to affect the formation of the
death-inducing signaling complex, including altered expression of
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death receptors, lack of caspase-8 activation, and cFLIP overexpres-
sion.23 The same study also reported an important expression of
cFLIP in MF biopsies. However, the ex vivo sensitivity of primary
circulating SzS cells to death-inducing ligands from the TNF
family has never been reported to date. In the present work, we
analyzed the sensitivity of primary ex vivo cultured circulating
tumor cells from 16 patients with SzS to soluble FasL and
TRAIL-mediated apoptosis, as well as the expression of selected
molecules involved in their signaling.
Methods
Patient material and cell lines
Peripheral blood leukocytes (PBL) from patients with SzS were obtained
after Ficoll isolation and frozen in fetal calf serum and 10% dimethyl
sulfoxide until use. All the experiments described in the present work were
performed with frozen PBL from patients with SzS diagnosed accordingly
to ISCL criteria. Tumor burden (reported in Table 1) is defined as the
percentage of circulating SzS cells and determined on sections of formalin-
fixed peripheral blood buffy coats. T-cell receptor (TCR) rearrangement
was positive for all the patients with SzS included in the present study.
CD4/CD8 ratios are reported for each patient in Table 1. Donation of blood
by patients or healthy volunteers in this study conformed to University of
Pennsylvania institutional review board-approved protocol, and informed
consents were obtained in accordance with the Declaration of Helsinki. The
SzS cell line HUT78 was from the American Type Culture Collection
(Manassas, VA). The MF cell line MyLa and the SzS cell line SeAx were
kindly given by Prof K. Kaltoft and Prof H. Bachelez (Inserm, Hoˆpital
Saint-Louis, Paris, France).
Sorting of CD4/CD7 or CD4/CD26 tumor cells
After thawing, CD4/CD7 or CD4/CD26 cells from patients with SzS
and healthy donors (HD) were magnetically sorted using depletion of CD7
or CD26 cells followed by the positive selection of CD4 cells with an
AutoMacs (Miltenyi Biotech, Bergisch Gladbach, Germany). For the
depletion of CD7 or CD26 cells, total PBL were stained with a
phycoerythrin-conjugated anti-CD7 (clone M-T701; BD Biosciences, San
Jose, CA) or anti-CD26 antibody (clone M-A261) and anti-phycoerythrin-
conjugated beads (Miltenyi Biotech). The CD26 fraction was collected,
labeled with anti-CD4-conjugated beads, and the CD4 fraction was
collected.
Analysis of the expression of death receptors
PBL from patients with SzS and HD were stained with monoclonal
antibodies to CD4 (clone RPA-T4) and CD7 (clone M-T701) or CD26
(clone M-A261; all from BD Pharmingen), and monoclonal antibodies to
Fas, TRAIL-receptor 1 (DR4, clone HS101), 2 (DR5, clone HS201),
3 (DcR1, clone HS301), and 4 (DcR2, clone HS402; Apotech, Lausen,
Switzerland). Flow cytometric analysis was performed on a FACScan with
the CellQuest Software (BD Biosciences, Allschwil, Switzerland).
Induction and analysis of apoptosis
Fresh (CTCL cell lines) or thawed (SzS and HD) cells were incubated at
106/mL in 96-well plates in 200 l of RPMI 1640 medium (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal calf serum and antibiotics. SzS
and HD CD4 cells or CTCL cell lines were treated with increasing doses
of soluble recombinant FasL (SuperFasLigand; Apotech), MegaFasLigand
(kindly provided by Apoxis S.A./Topotarget Switzerland, Lausanne, Swit-
zerland) or soluble recombinant TRAIL (SuperKillerTRAIL; Apotech) for
6 to 8 hours. Early apoptosis of the treated cells was analyzed by flow
cytometry after staining with annexin-V (BD Pharmingen) and propidium
iodide (Sigma-Aldrich, St Louis, MO). When indicated, cells were treated
overnight with 100 IU/mL recombinant IFN- or IFN- (Peprotech,
London, United Kingdom) before treatment with SuperFasLigand.
Quantitative reverse transcription polymerase chain reaction
Total RNA were extracted with a QIAgen Mini Kit upon manufacturer’s
instructions and subjected to DNase I (Qiagen, Basel, Switzerland)
treatment. Two micrograms of RNA were converted into cDNA using
SuperScript II (Qiagen). The expression of cFLIP in purified CD4/CD26
(magnetic cell sorting; Miltenyi Biotech) cells was compared with 3 stably
expressed housekeeping genes, namely HsEEF1A1, GusB, and ALAS. The
primers used for cFLIP cDNA amplification were CCAGAAGTACAAG-
CAGTCTGTTCAA (forward) and TTGGATTGCTGCTTGGAGAA
(reverse).
Statistical analysis
When indicated, unpaired Student t test was applied. Differences were
considered significant for P values less than.05.
Results
Heterogeneous FasL sensitivity in cutaneous lymphoma cell
lines and circulating CD4 cells from patients with SzS
Upon analyzing the sensitivity of a large number of cell lines to
FasL, we could show that 1 of 3 CTCL cell lines was resistant to
apoptosis when exposed in vitro to a hexameric form of soluble
FasL (SuperFasL) that has previously been shown to be a potent
inducer of Fas-mediated apoptosis in Fas expressing cell lines
(Figure 1C and data not shown). As recently shown by Braun et
al,23 we observed, with the use of a different apoptosis assay, that in
the FasL-resistant SeAx cell line, the loss of sensitivity to soluble
FasL correlated with a loss of Fas surface expression compared
with the 2 other cell lines (HUT78 and MyLa; Figure 1C).
Table 1. Characteristics of the SzS patients included in the study
Patient no.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Percentage SzS cells 90 99 82 99 25 86 85 90 91 18 20 15 49 91 23 21
CD4/CD8 ratio 30 707 42 288 2 210 90 22.8 95 2.3 9.3 8 ND 115 9 40
FasL sensitivity – – – – – – – – –       
Fas expression – –    –  –        
TRAIL sensitivity – – – – – – – – – – – – – – – –
DR5 expression – – – – – – – – – – – – – – – –
cFLIP expression ND ND    ND  ND  ND  ND ND   
Percentage of SzS cells was determined by flow cytometry or immunostaining of CD4/CD26 cells in peripheral blood after cytospin. Ratios are calculated as follows:
number of CD8/mL divided by number of CD4/mL of blood. CD4 cells from patients with SzS were considered sensitive to FasL for 60% annexin-V-/PI-CD4 cells by flow
cytometry. Fas was considered to be significantly expressed when the FasMFI was2 in CD4 SzS cells.
ND indicates not determined; –, negative;, positive/moderate; and, positive/high.
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To understand the cause of the above observed resistance to
soluble FasL in CD4 cells from patients with SzS, we analyzed
the expression of Fas on CD4 cells from HD and patients with
SzS. In HD, Fas expression on CD4 cells was quite strong and
varied little from donor to donor (mean fluorescence intensity
[MFI] 	 4.9 
 1.09) (Figure 1A). This was not the case in patients
with SzS, in which Fas expression on CD4 cells varied consider-
ably among patients. Four of 16 (25%) patients with SzS (patients
1, 2, 6, and 8), exhibited a decreased level of Fas expression on
CD4 (mean MFI 	 1.7) cells compared with HD (mean
MFI 	 4.75). The remaining 12 of 16 patients (75%) revealed
similar (patients 3, 4, 7, 11, 13, 15 and 16; mean MFI	 5) or
higher (patients 5, 9, 10, 12 and 14; mean MFI	 8.2) levels of Fas
expression on CD4 cells compared with HD. Because tumor cells
comprise only a fraction of the total CD4 cells, analysis of Fas
expression was also specifically analyzed on CD4/CD7/CD26
cells that are known to be the phenotypic markers for tumor cells
in patients with SzS. In both HD and SzS CD4 cells, no
significant difference in Fas expression was observed between
the CD26/CD7 and the CD26/CD7 subpopulations, indicat-
ing that the observed loss of Fas expression on CD4 cells in
patients with SzS is not selective for the tumor population of
CD4 cells (data not shown).
To analyze the sensitivity of circulating CD4 cells from
patients with SzS and HD to FasL, fresh or thawed PBL were
exposed in vitro to soluble FasL (SuperFasL), and apoptosis was
assessed by annexin-V/PI staining. In the 10 HD tested, FasL
induced apoptosis of CD4 cells in a dose-dependent manner, with
an average of 50% apoptosis (46.5
 6.5% [SD]) occurring after
8-hour exposure to 100 ng/mL of soluble FasL (Figure 1A). In
patients with SzS CD4 cells, the degree of apoptosis induced by
soluble FasL under the same conditions varied significantly among
Figure 1. Heterogeneous Fas expression and loss
of FasL sensitivity in SzS patient CD4 cells.
(A) CD4 cells from HD (n 	 10) and patients with SzS
(n 	 16) were subjected to FasL-induced apoptosis.
Six to 8 hours after FasL exposure (100 ng/mL), cell
viability was assessed by flow cytometry according to
annexin-V and PI staining (top panel). CD4 cells from
healthy donors (HD, n 	 10, ) and patients with SzS
(n 	 16, f) were stained with a fluorescein isothiocya-
nate (FITC)–anti-Fas (CD95) antibody or a FITC-
isotype-matched control and analyzed by flow cytom-
etry. MFI expresses the ratio between the MFI of cells
stained with the anti-Fas and the MFI obtained with
cells stained with the isotype control antibody (bottom
panel). Right panels show representative Fas expres-
sion patterns (CD95 antibody, bold histogram; control
isotype, thin histogram) in selected individuals. (B)
Correlation between FasL-induced apoptosis and tu-
mor burden in patients with SzS. (C) Sensitivity to FasL
and Fas expression (100 ng/mL) in the CTCL cell lines
HUT78 (SzS), MyLa (MF), and SeAx (SzS).
4782 CONTASSOT et al BLOOD, 1 MAY 2008  VOLUME 111, NUMBER 9
 For personal use only. at UNIVERSITAETSSPITAL on February 19, 2009. www.bloodjournal.orgFrom 
patients. Within the 16 patients with SzS tested, CD4 cells from
9 of 16 patients with SzS (56%, patients 1-9) were significantly
(P  .05) more resistant to soluble FasL-mediated apoptosis
(90 
 6.9% viable cells) than HD CD4 cells (Figure 1A, Table 1).
In the remaining 7 patients with SzS (44%, patients 10-16)
sensitivity to FasL was similar to that of HD (mean 46.8 
 11.3%
apoptotic cells) (Figure 1A and Table 1). Furthermore, a certain
degree of correlation (R2 	 0.54) between FasL-resistance and
tumor burden was observed (Figure 1B). It is noteworthy that in
patients with a high tumor burden ( 80% circulating SzS cells)
FasL was not able to induce apoptosis of CD4 cells (89.5%
 15%
viable CD4 cells), whereas an average of 50% CD4 cell
apoptosis (51.6 
 17.3%) was observed in patients with low or
medium ( 50% circulating SzS cells) tumor burden (Figure 1B,
Table 1).
In 4 of 16 (25%) patients with SzS, the significantly reduced Fas
expression on CD4 cells was correlated with significant resistance
to FasL-induced apoptosis (patients 1, 2, 6, and 8; Figure 1A). In
7 of 16 (43.75%) patients with SzS, CD4 Fas expression
correlated well with sensitivity to FasL-induced apoptosis (patients
10-16). Finally, in the remaining 5 of 16 (31.25%) patients with
SzS, significant resistance to FasL-induced apoptosis was observed
despite CD4 cell Fas expression levels similar or higher than that
observed in HD (patients 3, 4, 5, 7, and 9). The above observations
indicate that decreased Fas expression on SzS CD4 cells was not
the sole mechanism responsible for resistance to soluble FasL.
Overexpression of the cFLIP gene in circulating tumor cells
from patients with SzS
The observation that 5 of 16 patients with SzS (patients 3, 4, 5, 7,
and 9) CD4 cells were resistant to soluble FasL-induced apopto-
sis, despite significant Fas expression, suggests that molecular
mechanisms other than loss of Fas-expression may account for the
observed apoptosis resistance. To assess whether the intracellular
death receptor-mediated apoptosis inhibitor cFLIP could be in-
volved in apoptosis resistance, quantitative cFLIP real-time poly-
merase chain reaction (RT-PCR) was performed on sorted CD4/
CD26 cells from the 5 patients described above and compared
with Fas-expressing FasL-sensitive patients with SzS (n 	 4,
patients 11, 14, 15, and 16) and HD (n	 5). The magnetically
sorted CD4/CD26 populations exhibited a purity of more than
95% (data not shown). In the 5 tested CD4/CD26 populations
from FasL-resistant patients with SzS, the relative expression of
cFLIP was significantly increased compared with CD4/CD26
cells from FasL-sensitive patients with SzS (1.9 
 0.26 vs
0.8 
 0.17, respectively; P  .05; Figure 2, Table 1) and HD
(1.9 
 0.26 vs 0.45 
 0.15, respectively; P  .05; Figure 2, Table
1). The same analysis was performed in the HUT78, MyLa, and
SeAx CTCL cell lines, and cFLIP gene expression was found to be
similar to that measured in healthy donors (0.47
 0.45 vs
0.45 
 0.17, respectively; P 	 not significant; Figure 2). These
data suggest that cFLIP overexpression may be associated with
resistance to FasL-mediated apoptosis in Fas-expressing CD4
cells in patients with SzS.
CD4 cells from patients with SzS are resistant to TRAIL, and
the CD4/26 tumor cell population selectively lacks surface
TRAIL-R2 (DR5)
Because soluble TRAIL is in clinical development for the treatment
of cancer, we tested the sensitivity of CD4 cells from HD and
patients with SzS to soluble TRAIL. In contrast to CTCL cell lines
and, to a lesser extent HD CD4 cells, which are both shown to be
sensitive to soluble TRAIL in a dose-dependent manner, CD4
cells from all 16 (100%) tested patients with SzS were completely
resistant to TRAIL-induced apoptosis in vitro (Figure 3A, Table 1).
Furthermore, the observed resistance to TRAIL-induced apoptosis
in patients with SzS was independent of tumor burden (Table 1).
To further investigate the cause of resistance to TRAIL, the
expression of the death receptors TRAIL-receptors 1 (DR4) and
2 (DR5) and the decoy receptors TRAIL receptors 3 (DcR1) and
4 (DcR2) was investigated by fluorescence-activated cell sorting in
PBL from 10 HD and 16 patients with SzS. No difference of
expression of DR4 and DcR1 was found between HD and patients
with SzS on total CD4 cells or CD4 CD26 cells (Figure 3B,C).
By contrast, the expression of both TRAIL-receptor 2 (DR5) and
DcR2 were found to be significantly decreased in total CD4 cells
from patients with SzS compared with HD (Figure 3B, Table 1). It
is noteworthy that the observed loss in TRAIL-receptor 2 (DR5)
and DcR2 expression selectively affected the CD4/CD26 cells
from patients with SzS (Figure 3B). Taken together, these data
reveal a selective loss of TRAIL-receptor 2 (DR5), the major
receptor involved in TRAIL-induced apoptosis, in a tumor-
restricted manner.
A novel hexameric form of FasL (MegaFasL) or preincubation
with IFN-/ could partially overcome the resistance of SzS
CD4 cells to apoptosis
CD4 cells from patients resistant to apoptosis induced by the
above agents as well as commercially available soluble FasL
(SuperFasL) were exposed to a novel genetically engineered
hexameric form of soluble FasL (megaFasL [MFL]). For this
experiment, 4 FasL-resistant patients were selected (patients
6, 7, 8, and 9; see Figure 1A, Table 1). By contrast to SuperFasL,
MFL was able to induce significant apoptosis in circulating tumor
cells from 3 of 4 (75%) of the selected patients (patients 7, 8, and
9). In these patients, the average IC50 after 8 hours in vitro MFL
exposure ranged from 3 to 50 ng/mL, as opposed to more than
1 g/mL with SuperFasL. No apoptosis was observed in patient 6
in whom Fas expression on CD4 cells was completely absent
(Figure 4).
IFN- has proven clinical efficacy in the treatment of CTCL
including SzS. To determine whether IFN can affect the sensitivity
to FasL, CD4 cells from 2 selected patients with SzS with low Fas
Figure 2. cFLIP is overexpressed in SzS CD4/CD26 cells. cDNA from HD
(n 	 5), Fas-expressing FasL-resistant SzS (n 	 5, patients 3, 4, 5, 7, and 9),
Fas-expressing FasL-sensitive (n 	 4, patients 11, 14, 15, and 16) CD4/CD26
sorted cells and HUT78, MyLa, and SeAx cell lines were amplified using cFLIP
specific primers and compared with HsEEF1A1, GusB, and ALAS expression.
Mean (
 SD) of the relative expression is reported.
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expression (patients 1 and 2) and from 2 healthy donors (HD 1 and
2) were exposed in vitro overnight to 100 IU/mL IFN- or IFN-
and subsequently exposed to 100 ng/mL of SuperFasL. Exposure to
either IFN- or IFN- resulted in a 40% to 70% increase in Fas
expression on the surface of CD4 cells in 2 of 2 HD and 2 of
2 patients with SzS (Figure 4B top panels). When apoptosis was
assessed under the same conditions, the observed increased Fas
expression upon exposure to IFN- or IFN- was associated with a
significant (40%-80%) increase in FasL-mediated apoptosis (Fig-
ure 4B bottom panels).
Discussion
In the present work, we demonstrate that in patients with SzS,
CD4 T cells harbor significant defects in death receptor-mediated
apoptosis signaling. These defects affect both the FasL and TRAIL
signaling pathways and are associated in all cases with either a loss
of expression of the cell surface receptor for these 2 ligands, or an
increased expression of the gene encoding the intracellular apopto-
sis inhibitor cFLIP. Furthermore, we show that in the case of Fas, at
least, this signaling defect can be circumvented in a potentially
therapeutically meaningful manner in vitro either with a geneti-
cally engineered hexameric form of FasL or by pre-exposure to
IFN- or IFN-.
Appropriate Fas-mediated cell death is essential for adequate
control of lymphocyte homeostasis. It is noteworthy that elimina-
tion of T cells after encountering a specific antigen or superantigen
proceeds via activation-induced cell death, a process that is
dependent on appropriate Fas signaling of cell death. Furthermore,
in both mice and humans, Fas gene mutations leading to defective
Fas/signaling result in lymphoproliferative disorders as a conse-
quence of lymphocyte accumulation.24,25 Because in CTCL, tumor
cells have been demonstrated to be long-lived activated CD4
cells, defects in Fas-mediated apoptosis have been previously
proposed based on studies of protein expression, but the functional
consequences and detailed analyses of Fas signaling in CTCL is
lacking.26 It has recently been shown that apoptosis defects exist in
Figure 3. Tumor-restricted loss of DR5 and TRAIL
resistance in SzS patient CD4 cells. (A) Cells from
HD, patients with SzS and CTCL cell lines were exposed
to increasing doses of soluble TRAIL. Viability was
determined upon annexin-V/PI staining. One representa-
tive of 3 experiments. (B) Mean (
 SD) expression of
TRAIL-receptors in CD4 cells from healthy donors
(gray histogram, n 	 10) and patients with SzS (black
histogram, n 	 16). P  .05. (C) Representative TRAIL-
receptor expression profile in HD and patients with SzS.
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CTCL cells, but the majority of the reported functional data were
obtained with 4 established CTCL cell lines, a setting that does not
necessarily adequately reflect the clinical situation.23 In the present
work, we specifically analyzed apoptosis defects in ex vivo primary
SzS cells from 16 patients.
Using immunohistochemistry, decreased Fas expression by
semiquantitative analysis of anti-Fas labeling of skin-infiltrating
CD4 cells has been reported in tumor-stage MF and CD30 large
cutaneous large T-cell lymphoma.26 Likewise, in 4 and 3 cases of
SzS, Dereure et al27 and Meech et al,28 respectively, provide data
showing that Fas expression is decreased on circulating CD4 or
CD45RO-positive cells without further specification of the T-cell
phenotype.27,28 In the present work on a significant number of
patients with SzS, we functionally demonstrate for the first time
that, compared with healthy donors, circulating CD4 cells from
patients with SzS are completely resistant to soluble FasL in 56%
of cases. It is noteworthy that this functional defect in Fas signaling
is only accounted for by a loss of Fas expression in 44% of the
Fas-resistant cases, and in such cases, the loss of Fas expression
was not restricted to CD4/CD26 cells phenotypically consistent
with the tumor cell population. The cause of the observed loss of
Fas expression on tumoral and nontumoral CD4T cells of a subset
of patients with SzS remains to be determined. Fas gene mutations
or splice variants have been reported in MF but no data are
available for SzS; moreover, the latter would not account for the
observed loss of Fas expression on nontumoral CD4 T cells of
patients with SzS.29,30 A possible explanation that remains to be
investigated is that the Th2 cytokine milieu that predominates in
SzS31 may affect Fas expression and/or susceptibility to Fas-
mediated apoptosis in CD4 cells. In support of this, in a recent
report, Zhang et al32 show that Th2 cells are more resistant to either
TRAIL- or FasL-mediated apoptosis than Th1 cells. Likewise, the
Th2 cytokine IL-4 has been shown to protect tumor cells from
FasL-mediated apoptosis.33
Among genes that have been suggested to be modulated by Th2
cytokines is cFLIP, a cytoplasmic protein highly homologous to
caspases 8 and 10 that is a potent inhibitor of death-receptor
mediated apoptosis. The Th2 cytokine IL-4 has been shown to
protect solid tumor cells from FasL-mediated apoptosis via up-
regulation of antiapoptotic proteins including FLIP.33 cFLIP has
been shown to be strongly expressed in skin biopsies of MF
patients by immunohistochemistry. The same study reported cFLIP
expression in the PBL of patients with SzS without specifically
looking at CD4/CD26 and at levels and frequency not distinct
from that found in healthy donor PBL.23 In the present work, we
quantified cFLIP expression in sorted CD4/CD26 tumor cells
from the 5 FasL-mediated apoptosis-resistant, Fas-expressing
patients with SzS. cFLIP overexpression was found in the 5 tested
CD4/CD26 cells from Fas-expressing FasL-resistant patients
with SzS, irrespective of the tumor burden. Such an overexpression
was not observed in CD4/CD26 cells from FasL-sensitive
patients with SzS, healthy donors, and CTCL cell lines, suggesting
Figure 4. Resistance to apoptosis induced by
soluble FasL can be overcome in patients with SzS.
(A) Selected resistant patients expressing low levels
(patients 7, 8, and 9) or no Fas (patient 6) were
exposed to increasing doses of MFL. Viability was
assessed 6 to 8 hours after MFL treatment by flow
cytometry analysis of annexin-V/PI staining. One repre-
sentative of 2 experiments. In the same way, Fas-
expressing HUT78 and MyLa and Fas-negative SeAx
cell lines were treated with MFL. (B) Two selected HD
(1 and 2) and patients with SzS (1 and 2) were exposed
to 100 IU/mL IFN- (left panels) or IFN- (right panels)
before treatment with 100 ng/mL FasL. Increase of the
measured Fas-MFI (top panels) and increase of the
annexin-V/PI apoptotic fraction (bottom panels) are
reported.
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that, as reported for other cancers, increased expression of cFLIP
may contribute to defective death-receptor signaling. Whether Th2
cytokines such as IL-4 are responsible for the high levels of cFLIP
mRNA observed selectively in the CD4/CD26 cell population of
patients with SzS remains to be determined. Nevertheless, the
observed increased cFLIP expression in SzS is likely to be of
relevance in disease pathogenesis as suggested in mouse models of
lymphoma in which enforced overexpression of cFLIP has been
shown to favor tumor progression.21,22 In their recent publication,
Braun et al23 show an increased expression of cFLIP in CTCL cell
lines compared with acute lymphoid leukemia cell lines. We also
found such an increased expression in CTCL cell lines and primary
tumor cells from patients with SzS. However, unlike the Western
blot data of Braun et al,23 we found, using qRT-PCR, significant
differences in cFLIP expression between FasL-resistant CD4/
CD26 cells from patients with SzS and CD4/CD26 cells from
HD, suggesting that this overexpression may directly contribute
to Fas resistance despite conserved Fas expression in patients
with SzS.
The death ligand TRAIL is considered to be a promising
anticancer agent. Agonistic antibodies against DR4,34 or DR5,35 or
recombinant soluble TRAIL36-39 are able to induce apoptosis in
cancer cells of various origins in vitro and in vivo without affecting
normal cells. TRAIL is currently being evaluated clinically in a
phase Ib as an anticancer agent in a variety of solid tumors and
hematologic malignancies. Gene expression profiling by qRT-PCR
showed an overexpression of TRAIL in progressive CTCL,40 but
the expression of TRAIL receptors and sensitivity of SzS primary
tumor cells to TRAIL has not been reported to date. Here, we
provide novel data revealing that circulating CD4 cells from
patients with SzS are completely resistant to soluble TRAIL and
such patients harbor a significant, tumor cell–restricted, loss of
TRAIL-receptor 2 (DR5). It is noteworthy that DR5 was expressed
by CD4/CD26 nontumor cells from patients with SzS, thus
suggesting that the total resistance to TRAIL is most likely a
tumor-associated event. Loss or altered expression of DR5 has
been reported previously for certain other cancers.10,13 This data
suggests that the use of TRAIL as single anticancer agent may be
ineffective in SzS.
In the present work, we have investigated 2 approaches to
circumvent the observed resistance of PBL from patients with SzS
to apoptosis mediated by Fas signaling. As previously shown for
acute myeloid leukemia,41 the use of recently developed soluble
hexameric form of FasL, namely MFL, allowed us to induce
significant apoptotic cell death in all the tested SzS tumor cell
samples. The reason of the increased efficiency of MFL compared
with other forms of soluble FasL remains unknown. A possible
increase of the recruitment of weakly expressed Fas at the surface
of tumor cells by MFL due to its hexameric nature (compared with
mono or trimers) or to its own conformation (compared with the
SuperFasL hexamer used in this study) may be an explanation. It is
noteworthy that the low observed IC50 of MFL on SzS PBL in vitro
suggests that there may be a therapeutic window of opportunity for
the uses of MFL in the treatment of SzS. Indeed, circulating levels
of MFL that were 10 to 100 times higher than the concentrations
necessary to kill tumor cells in vitro were attained after injection of
MFL in mice, in the absence of severe systemic toxicity.42
Accordingly, MFL treatment of mice bearing xenograft tumors
of ovarian cancer resulted in a decrease in tumor growth at
tolerated doses. On the basis of these and other favorable results,
MFL is currently being tested as an anti-tumor agent in phase I
clinical trials.
The 2 main objectives of SzS treatment are (1) to favor the
elimination of tumor cells and (2) to restore a normal immune
response. Multimodality therapy, which is now the standard of care
for advanced CTCL, includes the use of agents that induce
apoptosis such as PUVA or, more recently, bexarotene, a retinoid X
receptor specific agent.43 Combinations of apoptotic agents and
agents targeting the activation of immune cells are known to induce
higher therapeutic responses than apoptotic agents alone.44 As an
example, treatment associating PUVA and IFN- leads to a higher
clinical response in CTCL patients than PUVA alone. Here we
investigated the effect of IFN- and IFN- on the sensitivity of
patients with SzS PBL to soluble FasL and could demonstrate that
pretreatment with either of these cytokines could increase Fas
expression on SzS tumor cells and simultaneously increase their
sensitivity to soluble FasL.
Taken together, our observations suggest that resistance to
apoptosis induced by the TNF ligands FasL and TRAIL occur in a
significant subset of patients with SzS. This may contribute to the
observed accumulation of CD4/CD26 clonal T cells in the
disease and should be taken into account for the design of
therapeutic strategies in SzS.
Acknowledgments
This work was supported by the Fonds National Suisse de la
Recherche Scientifique (L.E.F.), Oncosuisse (L.E.F./E.C.), the
Fondation Louis Jeantet and the EU Transeurope/Transnet, and a
Translation Research grant from the Leukemia and Lymphoma
Society (A.H.R.).
Authorship
Contribution: E.C., K.K., S.R., O.G., M.D., and R.S performed the
experiments; A.H.R. and L.E.F. designed the research; E.C. and
L.E.F. wrote the article.
Conflict-of-interest disclosure: L.E.F. declares a financial inter-
est in Topo-target, a company whose potential product was studied
in the present work. The remaining authors declare no competing
financial interests.
Correspondence: Lars E. French, Department of Dermatology,
Zurich University Hospital, Gloriastrasse 31, 8091 Zu¨rich, Switzer-
land; e-mail: lars.french@usz.ch.
References
1. Rook AH, Vowels BR, Jaworsky C, Singh A, Les-
sin SR. The immunopathogenesis of cutaneous
T-cell lymphoma. Abnormal cytokine production
by Sezary T cells. Arch Dermatol. 1993;129:486-
489.
2. Vowels BR, Lessin SR, Cassin M, et al. Th2 cyto-
kine mRNA expression in skin in cutaneous T-cell
lymphoma. J Invest Dermatol. 1994;103:669-673.
3. Dummer R, Heald PW, Nestle FO, et al. Sezary
syndrome T-cell clones display T-helper 2 cyto-
kines and express the accessory factor-1
(interferon-gamma receptor beta-chain). Blood.
1996;88:1383-1389.
4. Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of
cutaneous T-cell lymphoma with extracorporeal
photopheresis monotherapy and in combination
with recombinant interferon alfa: a 10-year expe-
rience at a single institution. J Am Acad Dermatol.
1996;35:946-957.
5. Rook AH, Wood GS, Yoo EK, et al. Interleukin-12
therapy of cutaneous T-cell lymphoma induces
lesion regression and cytotoxic T-cell responses.
Blood. 1999;94:902-908.
6. Ashkenazi A, Dixit VM. Death receptors: signaling
and modulation. Science. 1998;281:1305-1308.
4786 CONTASSOT et al BLOOD, 1 MAY 2008  VOLUME 111, NUMBER 9
 For personal use only. at UNIVERSITAETSSPITAL on February 19, 2009. www.bloodjournal.orgFrom 
7. Ashkenazi A, Dixit VM. Apoptosis control by
death and decoy receptors. Curr Opin Cell Biol.
1999;11:255-260.
8. Lee SH, Shin MS, Park WS, et al. Alterations of
Fas (Apo-1/CD95) gene in non-small cell lung
cancer. Oncogene. 1999;18:3754-3760.
9. Lee SH, Shin MS, Park WS, et al. Alterations of
Fas (APO-1/CD95) gene in transitional cell carci-
nomas of urinary bladder. Cancer Res. 1999;59:
3068-3072.
10. Lee SH, Shin MS, Kim HS, et al. Alterations of the
DR5/TRAIL receptor 2 gene in non-small cell lung
cancers. Cancer Res. 1999;59:5683-5686.
11. Shin MS, Park WS, Kim SY, et al. Alterations of
Fas (Apo-1/CD95) gene in cutaneous malignant
melanoma. Am J Pathol. 1999;154:1785-1791.
12. Lee SH, Shin MS, Kim HS, et al. Somatic muta-
tions of Fas (Apo-1/CD95) gene in cutaneous
squamous cell carcinoma arising from a burn
scar. J Invest Dermatol. 2000;114:122-126.
13. Lee SH, Shin MS, Kim HS, et al. Somatic muta-
tions of TRAIL-receptor 1 and TRAIL-receptor 2
genes in non-Hodgkin’s lymphoma. Oncogene.
2001;20:399-403.
14. Park WS, Oh RR, Kim YS, et al. Somatic muta-
tions in the death domain of the Fas (Apo-1/
CD95) gene in gastric cancer. J Pathol.
2001;193:162-168.
15. Dutton A, O’Neil JD, Milner AE, et al. Expression
of the cellular FLICE-inhibitory protein (c-FLIP)
protects Hodgkin’s lymphoma cells from autono-
mous Fas-mediated death. Proc Natl Acad Sci
U S A. 2004;101:6611-6616.
16. Abedini MR, Qiu Q, Yan X, Tsang BK. Possible
role of FLICE-like inhibitory protein (FLIP) in che-
moresistant ovarian cancer cells in vitro. Onco-
gene. 2004;23:6997-7004.
17. Irisarri M, Plumas J, Bonnefoix T, et al. Resis-
tance to CD95-mediated apoptosis through con-
stitutive c-FLIP expression in a non-Hodgkin’s
lymphoma B cell line. Leukemia. 2000;14:2149-
2158.
18. Korkolopoulou P, Goudopoulou A, Voutsinas G, et
al. c-FLIP expression in bladder urothelial carci-
nomas: its role in resistance to Fas-mediated ap-
optosis and clinicopathologic correlations. Urol-
ogy. 2004;63:1198-1204.
19. Lee SH, Kim HS, Kim SY, et al. Increased expres-
sion of FLIP, an inhibitor of Fas-mediated apopto-
sis, in stomach cancer. APMIS. 2003;111:309-
314.
20. Bullani RR, Huard B, Viard-Leveugle I, et al. Se-
lective expression of FLIP in malignant melano-
cytic skin lesions. J Invest Dermatol. 2001;117:
360-364.
21. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biber-
feld P, Grandien A. The inhibitor of death receptor
signaling, FLICE-inhibitory protein defines a new
class of tumor progression factors. J Exp Med.
1999;190:1025-1032.
22. Medema JP, de Jong J, van Hall T, Melief CJ, Of-
fringa R. Immune escape of tumors in vivo by ex-
pression of cellular FLICE-inhibitory protein. J
Exp Med. 1999;190:1033-1038.
23. Braun FK, Fecker LF, Schwarz C, et al. Blockade
of death receptor-mediated pathways early in the
signaling cascade coincides with distinct apopto-
sis resistance in cutaneous T-cell lymphoma
cells. J Invest Dermatol. 2007;127:2425-2437.
24. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Muta-
tions in Fas associated with human lymphoprolif-
erative syndrome and autoimmunity. Science.
1995;268:1347-1349.
25. Nagata S. Apoptosis by death factor. Cell. 1997;
88:355-365.
26. Ni X, Zhang C, Talpur R, Duvic M. Resistance to
activation-induced cell death and bystander cyto-
toxicity via the Fas/Fas ligand pathway are impli-
cated in the pathogenesis of cutaneous T cell
lymphomas. J Invest Dermatol. 2005;124:741-
750.
27. Dereure O, Portales P, Clot J, Guilhou JJ. De-
creased expression of Fas (APO-1/CD95) on pe-
ripheral blood CD4 T lymphocytes in cutaneous
T-cell lymphomas. Br J Dermatol. 2000;143:
1205-1210.
28. Meech SJ, Edelson R, Walsh P, Norris DA, Duke
RC. Reversible resistance to apoptosis in cutane-
ous T cell lymphoma. Ann N Y Acad Sci. 2001;
941:46-58.
29. Dereure O, Levi E, Vonderheid EC, Kadin ME.
Infrequent Fas mutations but no Bax or p53 muta-
tions in early mycosis fungoides: a possible
mechanism for the accumulation of malignant T
lymphocytes in the skin. J Invest Dermatol. 2002;
118:949-956.
30. van Doorn R, Dijkman R, Vermeer MH, Starink
TM, Willemze R, Tensen CP. A novel splice vari-
ant of the Fas gene in patients with cutaneous
T-cell lymphoma. Cancer Res. 2002;62:5389-
5392.
31. Kim EJ, Hess S, Richardson SK, et al. Immuno-
pathogenesis and therapy of cutaneous T cell
lymphoma. J Clin Invest. 2005;115:798-812.
32. Zhang XR, Zhang LY, Devadas S, Li L, Keegan
AD, Shi YF. Reciprocal expression of TRAIL and
CD95L in Th1 and Th2 cells: role of apoptosis in T
helper subset differentiation. Cell Death Differ.
2003;10:203-210.
33. Conticello C, Pedini F, Zeuner A, et al. IL-4 pro-
tects tumor cells from anti-CD95 and chemo-
therapeutic agents via up-regulation of antiapop-
totic proteins. J Immunol. 2004;172:5467-5477.
34. Chuntharapai A, Dodge K, Grimmer K, et al.
Isotype-dependent inhibition of tumor growth in
vivo by monoclonal antibodies to death receptor
4. J Immunol. 2001;166:4891-4898.
35. Ichikawa K, Liu W, Zhao L, et al. Tumoricidal ac-
tivity of a novel anti-human DR5 monoclonal anti-
body without hepatocyte cytotoxicity. Nat Med.
2001;7:954-960.
36. Naka T, Sugamura K, Hylander BL, Widmer MB,
Rustum YM, Repasky EA. Effects of tumor necro-
sis factor-related apoptosis-inducing ligand alone
and in combination with chemotherapeutic agents
on patients’ colon tumors grown in SCID mice.
Cancer Res. 2002;62:5800-5806.
37. Jin H, Yang R, Fong S, et al. Apo2 ligand/tumor
necrosis factor-related apoptosis-inducing ligand
cooperates with chemotherapy to inhibit ortho-
topic lung tumor growth and improve survival.
Cancer Res. 2004;64:4900-4905.
38. Ray S, Almasan A. Apoptosis induction in pros-
tate cancer cells and xenografts by combined
treatment with Apo2 ligand/tumor necrosis factor-
related apoptosis-inducing ligand and CPT-11.
Cancer Res. 2003;63:4713-4723.
39. Mitsiades CS, Treon SP, Mitsiades N, et al.
TRAIL/Apo2L ligand selectively induces apopto-
sis and overcomes drug resistance in multiple
myeloma: therapeutic applications. Blood. 2001;
98:795-804.
40. Nebozhyn M, Loboda A, Kari L, et al. Quantitative
PCR on 5 genes reliably identifies CTCL patients
with 5% to 99% circulating tumor cells with 90%
accuracy. Blood. 2006;107:3189-3196.
41. Greaney P, Nahimana A, Lagopoulos L, et al. A
Fas agonist induces high levels of apoptosis in
haematological malignancies. Leuk Res. 2006;
30:415-426.
42. Etter AL, Bassi I, Germain S, et al. The combina-
tion of chemotherapy and intraperitoneal
MegaFas Ligand improves treatment of ovarian
carcinoma. Gynecol Oncol. 2007;107:14-21.
43. Duvic M, Hymes K, Heald P, et al. Bexarotene is
effective and safe for treatment of refractory
advanced-stage cutaneous T-cell lymphoma:
multinational phase II-III trial results. J Clin Oncol.
2001;19:2456-2471.
44. Richardson SK, Lin JH, Vittorio CC, et al. High
clinical response rate with multimodality immuno-
modulatory therapy for Sezary syndrome. Clin
Lymphoma Myeloma. 2006;7:226-232.
APOPTOSIS DEFECTS IN SE´ ZARY SYNDROME T-CELLS 4787BLOOD, 1 MAY 2008  VOLUME 111, NUMBER 9
 For personal use only. at UNIVERSITAETSSPITAL on February 19, 2009. www.bloodjournal.orgFrom 
